BTAI On Other Exchanges

bioxcel therapeutics inc (BTAI) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bioxcel therapeutics inc (BTAI) Related Businessweek News

No Related Businessweek News Found

bioxcel therapeutics inc (BTAI) Details

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

18 Employees
Last Reported Date: 03/12/19
Founded in 2017

bioxcel therapeutics inc (BTAI) Top Compensated Officers

Founder, CEO, President, Secretary & Director
Total Annual Compensation: $701.6K
Chief Financial Officer
Total Annual Compensation: $129.1K
Senior VP & Chief Medical Officer
Total Annual Compensation: $403.1K
Chief Scientific Officer
Total Annual Compensation: $393.5K
Compensation as of Fiscal Year 2018.
bioxcel therapeutics inc
BioXcel Therapeutics, Inc. Presents at 2019 BIO International Conference, Jun-06-2019 09:00 AM

BioXcel Therapeutics, Inc. Presents at 2019 BIO International Conference, Jun-06-2019 09:00 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Vimal D. Mehta, Founder, CEO, President, Secretary & Director.

BioXcel Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-07-2019 09:00 AM

BioXcel Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-07-2019 09:00 AM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Vimal D. Mehta, Founder, CEO, President, Secretary & Director.

Bioxcel Therapeutics, Inc. Announces Positive Top Line Data from its Phase 1 Pharmacokinetic (PK) (Bioavailability) and Safety Study of BXCL501

BioXcel Therapeutics, Inc. announced positive top line data from its Phase 1 pharmacokinetic (PK) (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for the acute treatment of agitation across multiple neuropsychiatric indications. Administration of BXCL501 in the Phase 1 pharmacokinetic and safety study successfully achieved targeted exposure levels that were observed to be therapeutic in the Company’s prior IV Dex study and BTI intends to advance BXCL501 into a Phase 2 trial to evaluate efficacy in agitated schizophrenia patients. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance next wave of medicines in neuroscience and immuno-oncology. The IND-opening Phase 1 study was a double-blinded placebo-controlled, single-dose, dose-escalation study of BXCL501 that enrolled 42 adult volunteers across various dosing groups. The primary endpoints of the study were PK and safety, while secondary endpoints included assessment of pharmacodynamics (PD) and the relationship between BXCL501 concentrations and PD endpoints. Findings from the study indicate that BXCL501 rapidly achieved targeted exposure levels consistent with the levels observed in the intravenous (“IV”) Dex study in schizophrenia patients that the Company announced in November 2018. Results from the Phase 1 study also showed dose-proportional PK consistent with the IV Dex study with PD effects lasting 4 to 6 hours, which it believe are clinically favorable features. Additionally, clinical data from the study indicates BXCL501 was well tolerated. There were no serious adverse events. The most common adverse event was drowsiness, observed at rates similar to placebo. All adverse events were mild to moderate and transient. There was no clear sedative effect in comparison with placebo. Cardiovascular changes were not clinically meaningful. A maximum tolerated dose was not reached.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

BTAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTAI.
View Industry Companies

Industry Analysis


Industry Average

Valuation BTAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIOXCEL THERAPEUTICS INC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at